“The modulation of pain and inflammation at the bioelectric level offers a clear pathway for sustainable and effective management strategies.” — Wanni Davis, PhD, MBA, Chief Operating Officer, Electrome
Introduction
Pain and inflammation account for a disproportionate share of chronic disability, healthcare spending, and lost productivity worldwide. While pharmaceuticals remain foundational, their limitations, side effects, tolerance, addiction risk, and diminishing returns in complex or long-standing conditions have accelerated the search for new modalities (1,2). Bioelectric medicine, the targeted modulation of biological systems using controlled electrical energy, offers a fundamentally different pathway: intervening directly in the electrical signaling that shapes pain perception and immune activation (1,3). Within this transformative sphere, Electrome unites advances in neuroscience, engineering, and digital health to develop devices and protocols that use electricity as a medicine interrupting pathological pain circuits, resolving chronic inflammation, and restoring physiological balance where drugs often fall short (1,4,5).
The challenge of pain and inflammation
Acute pain is adaptive, alerting us to injury and prompting protective behaviors. For millions, however, pain persists beyond normal healing and becomes a disease entity in its own right (3). Inflammatory disorders from arthritis and Crohn’s disease to neuropathies and fibromyalgia compound this burden by driving tissue damage and immune dysregulation (3,6). Conventional regimens rely on NSAIDs, corticosteroids, disease-modifying agents, and, too often, opioids, an approach that carries significant risks, including organ toxicity, dependency, and overdose (6,7). Despite innovation, pain and inflammation remain leading drivers of quality-of-life loss and cost across health systems (7).
Rewriting the script: how bioelectricity works
Bioelectric interventions bypass many drug limitations by targeting the electrical code that underlies sensation and immunity. Every thought, movement, and pain signal is orchestrated by ionic currents and synaptic transmission (2). Devices such as transcutaneous electrical nerve stimulation, percutaneous stimulators, and implantable neurostimulators deliver precisely timed pulses that interfere with pain propagation along peripheral nerves and within the spinal cord (4). Newer systems pair sensors with algorithms to adapt in real time “closed-loop” control that tunes stimulation to a patient’s state across activity, rest, and flare-ups (4,8). Inflammation, likewise, is susceptible to targeted electrical modulation. The cholinergic anti-inflammatory pathway defined by Tracey and others shows that vagus nerve stimulation can reduce cytokine output and dampen excessive immune activity, with measurable effects in rheumatoid arthritis and inflammatory bowel disease (1,9).
Electrome’s precision advantage
Electrome integrates leading-edge device design with analytics for tailored, patient-specific therapy. Wearable and implantable stimulators incorporate biosensors for motion, temperature, pH, and local electrical activity, continuously streaming data to cloud-based learning models that refine therapy over time (1,4). “We are developing technologies that provide precise control over electric signaling in cells, offering new opportunities to treat chronic pain, inflammation, and other debilitating conditions,” notes CTO Erik A. Nilsen, PhD. In practice, every pulse, frequency, and waveform is informed not only by decades of clinical science but also by real-time patient context, maximizing relief while minimizing side effects (2,4).
Scientific evidence and evolving standards
Meta-analyses and randomized trials support electrical stimulation for neuropathic pain, fibromyalgia, osteoarthritis, and chronic low back pain (5,8). Closed-loop neuromodulation—now entering advanced studies—aims to improve outcomes in chronic migraine, rheumatoid arthritis, and multiple sclerosis by dynamically modulating neural-immune circuits (3,6,9). Carefully titrated stimulation of the vagus and other visceral nerves can alter cytokine profiles, immune cell function, and stress physiology, reframing inflammation as a treatable signaling imbalance (9).
Implications for healthcare systems
As health systems shift toward value-based care, modalities with equal or better outcomes at lower total cost gain traction. Electrome’s therapies can be delivered in clinics, at home, and with remote monitoring—reducing hospitalizations, drug burden, and prolonged rehab episodes (7,10). This flexibility is critical for aging populations and for patients in remote or resource-constrained settings, where digital, scalable pain and inflammation solutions are essential to twenty-first-century public health (7,10).
A patient-centered future
Reducing chronic pain and systemic inflammation improves more than metrics—it transforms daily life. Patients report lower pain scores, greater mobility, better sleep, and renewed participation at work and home. Early real-world data from Electrome programs suggest fewer emergency visits and faster recovery from sports and workplace injuries—impacts that may translate into significant savings for employers and payers (7,10,11). Chief Medical Officer Nevena Zubcevik, DO, underscores this mission: “Harnessing insights from bioelectric research will enable us to develop therapies that are not only innovative but also patient-centered, emphasizing individualized care.”
R&D and global leadership
Electrome supports continual R&D with pilot and pivotal trials across perioperative pain, atrial fibrillation, autoimmune flares, and metabolic inflammation (4). Collaborations with academic centers, device manufacturers, and international agencies accelerate adoption and evidence accrual. The company has also advanced regulatory strategies across FDA and CE pathways for a range of devices, laying the groundwork for global deployment of AI-enabled, cloud-connected stimulators and future extensions into regenerative and neuropsychiatric domains (4,8).
The road ahead
The most powerful solutions will merge bioelectric therapy with pharmacology, rehabilitation, and lifestyle change. Multimodal protocols combining drugs, devices, and behavioral programs are poised to deliver robust, durable outcomes for people living with pain and inflammatory disease (1,3,9). Electrome’s aim is not merely to supply technology, but to help establish global standards: building real-world evidence, supporting open science, and defining best practices for the bioelectric era.
References
- Bioelectronic Medicine: a multidisciplinary roadmap from biophysics to patient care. Front Integr Neurosci. 2024;18:1321872. https://www.frontiersin.org/journals/integrative-neuroscience/articles/10.3389/fnint.2024.1321872/full
- Next-Generation Bioelectric Medicine: Harnessing the Therapeutic Potential. Front Neurol. 2020;11:616529. https://pmc.ncbi.nlm.nih.gov/articles/PMC8370382/
- Singing the Body Electric: Exploring Bioelectronic Medicine. Pharmasalmanac. 2025. https://www.pharmasalmanac.com/articles/singing-the-body-electric-exploring-bioelectronic-medicine
- 8 Companies Developing Bioelectronic Devices. Nanalyze. https://www.nanalyze.com/2021/03/fda-approved-bioelectronic-devices/
- Grand View Research. Bioelectric Medicine Market Size and Share Report, 2030. https://www.grandviewresearch.com/industry-analysis/bioelectric-medicine-market
- New paper creates roadmap for the next generation of bioelectronic medicine. ScienceDaily. 2025. https://www.sciencedaily.com/releases/2025/01/250121162336.htm
- Electroceuticals/Bioelectric Medicine Market to Reach $40.5 Billion Globally by 2032. Allied Market Research. 2024. https://www.prnewswire.com/news-releases/electroceuticalsbioelectric-medicine-market-to-reach-40-5-billion-globally-by-2032-at-7-4-cagr-allied-market-research-302124096.html
- Bioelectronic Medicine Market Research Report 2025. GlobeNewswire. 2025. https://www.globenewswire.com
- Tracey KJ. The inflammatory reflex. Nature. 2002;420(6917):853-859. https://doi.org/10.1038/nature01321
- Bioelectronic Medicine: The Next New Frontier. YouTube (Northwell Health). 2024. https://www.youtube.com/watch?v=9SskZWo3SJY
- 5 Projects That Show the Incredible Future of Bioelectronic Medicine. MDDIOnline. 2025. https://www.mddionline.com/rd/5-projects-that-show-the-incredible-future-of-bioelectronic-medicine
What Comes Next: From Signals to Systems
In Bioelectric Science, Vol. VI, we will examine how closed-loop bioelectric platforms integrate with rehabilitation, behavioral therapy, and pharmacology—advancing comprehensive, patient-centered care for complex pain and inflammatory disorders.
Bioelectric Science Series Recap
Vol. I: The Future is Electric
Vol. II: The Signal Effect
Vol. III: Electric Immunity
Vol. IV: The Personalized Pulse
Vol. V: The Electric Brain
Vol. VI: Tackling Pain and Inflammation: The Bioelectric Solution
Vol. VII: Signals of the Self Bioelectricity, Consciousness, and Human Enhancement
Electrome: Bioelectric Science Series is published by Electrome Corporation as a frontier journal and cultural signal for the emerging field of frequency-based medicine. To collaborate, invest, or license, visit www.electrome.com.